Novel intraocular and systemic absorption drug delivery and efficacy of N-acetylcarnosine lubricant eye drops or carcinine biologics in pharmaceutical usage and therapeutic vision care

Fundamental and Clinical Pharmacology

Volumn 26, Issue 5, 2012, Pages 644-678

  Babizhayev, Mark A ^a,b   Khoroshilova Maslova, Inna P ^b   Kasus Jacobi, Anne ^c  

^a Innovative Vision Products Incorporated   (United States)

^b MOSCOW HELMHOLTZ RESEARCH INSTITUTE OF EYE DISEASES   (Russian Federation)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Age related macular degeneration and proliferative vitreoretinopathy; Carcinine and blindness prevention; Cataract; Light induced damage of photoreceptor cells; N acetylcarnosine lubricant eye drops; Vision care and age related ophthalmic diseases

Indexed keywords

CAN C; CARNOSINE; EYE DROPS; N ACETYLCARNOSINE; PLACEBO; PRODRUG; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; BLURRED VISION; CATARACT; CONTROLLED STUDY; CORNEA DISEASE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EYE INFLAMMATION; FEMALE; HUMAN; HYDROPHOBICITY; LIGHT STRESS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OPEN ANGLE GLAUCOMA; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL; PHOTORECEPTOR CELL; PRESBYOPIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DISEASE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; TREATMENT DURATION; VISION; VITREORETINOPATHY;

ADMINISTRATION, OPHTHALMIC; ANIMALS; CARNOSINE; CATARACT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DELIVERY SYSTEMS; EYE DISEASES; HUMANS; PRODRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITREORETINOPATHY, PROLIFERATIVE;

EID: 84861715346     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00963.x     Document Type: Article

References (119)

1. Resnikoff S., Pascolini D., Etya'ale D. et al. Global data on visual impairment in the year 2002. Bull. World Health Organ. (2004) 82 844-851. Epub 2004 Dec 14.
2. Dandona R., Dandona L. Socioeconomic status and blindness. Br. J. Ophthalmol. (2001) 85 1484-1488.
3. Congdon N., O'Colmain B., Klaver C.C. et al. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. (2004) 122 477-485.
4. Marrelli T.M. Handbook of home health standards and documentation guidelines for reimbursement, 2nd edn. Mosby, St Louis, 1994.
5. Yorston D. Cataract complications. Commun. Eye Res. J. (2008) 65 1-3.
6. Babizhayev M.A., Deyev A.I., Yermakova V.N. et al. N-acetyl-carnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides (2001) 22 979-994.
7. Babizhayev M.A., Deyev A.I., Yermakova V.N. et al. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R. D. (2002) 3 87-103.
8. Babizhayev M.A., Deyev A.I., Yermakova V.N., Remenschikov V.V., Bours J. Revival of the lens transparency with N-acetylcarnosine. Curr. Drug Ther. (2006) 1 91-116.
9. Babizhayev M.A., Deyev A.I., Yermakova V.N., Brikman I.V., Bours J. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs R. D. (2004) 5 125-139.
10. Babizhayev M.A. (2004) Method for topical treatment of eye disease and composition and device for said treatment. PCT Patent Application. International Publication Number WO 2004/028536 A1. International Publication Date: 8 April 2004.
11. Babizhayev M.A. Ophthalmic pharmacology of N-acetylcarnosine lubricant eye drops. J. Pharmacol. Toxicol. (2006) 1 201-233.
12. Babizhayev M.A. Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops. Rejuvenation Res. (2004) 7 186-198.
13. Babizhayev M.A., Yermakova V.N., Deyev A.I., Seguin M.-C. Imidazole-containing peptidomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans. J. Anti-Aging Med. (2000) 3 43-62.
14. Babizhayev M.A., Yermakova V.N., Sakina N.L., Evstigneeva R.P., Rozhkova E.A., Zheltukhina G.A. Nα-Acetylcarnosine is a prodrug of L-carnosine in ophthalmic application as antioxidant. Clin. Chim. Acta (1996) 254 1-21.
15. Babizhayev M.A., Guiotto A., Kasus-Jacobi A. N-Acetylcarnosine and histidyl-hydrazide are potent agents for multitargeted ophthalmic therapy of senile cataracts and diabetic ocular complications. J. Drug Target. (2009) 17 36-63.
16. Babizhayev M.A., Kasus-Jacobi A. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases. Curr. Clin. Pharmacol. (2009) 4 4-37.
17. Babizhayev M.A., Micans P., Guiotto A., Kasus-Jacobi A. N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: a clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50, 500 patients. Am. J. Ther. (2009) 16 517-533.
18. Babizhayev M.A., Burke L., Micans P., Richer S.P. N-Acetyl-carnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50, 000-patient population. Clin. Interv. Aging. (2009) 4 31-50. Epub 2009 May 14.
19. Babizhayev M.A. Current ocular drug delivery challenges for N-acetylcarnosine: novel patented routes and modes of delivery, design for enhancement of therapeutic activity and drug delivery relationships. Recent Pat. Drug Deliv. Formul. (2009) 3 229-265.
20. Gulewitsch W., Amiradzibi S. Uber das carnosin, eine neue organische Base des Fleischextraktes. Ber. Deutch. Chem. Ges. (1900) 33 1902-1903.
21. Babizhayev M.A., Seguin M.-C., Gueyne J., Evstigneeva R.P., Ageyeva E.A., Zheltukhina G.A. L-Carnosine (β-alanyl-L-histidine) and carcinine (β -alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid peroxidase activities. Biochem. J. (1994) 304 509-516.
22. Severin S.E. Problems concerned with the biological activity of naturally occurring imidazole compounds. Proceedings of Plen. Sess. Seventh International Biochemical Congress 1964, NY, pp. 45-61.
23. Boldyrev A.A., Severin S.E. The histidine-containing dipeptides, carnosine and anserine: distribution, properties and biological significance. Adv. Enzyme Regul. (1990) 30 175-194.
24. Lenney J.F. Specificity and distribution of mammalian carnosinase. Biochim. Biophys. Acta (1976) 429 214-219.
25. Jackson M.C., Kucera C.M., Lenney J.F. Purification and properties of human serum carnosinase. Clin. Chim. Acta (1991) 196 193-205.
26. Lenney J.F. Separation and characterization of two carnosine-splitting cytosolic dipeptidases from hog kidney (carnosinase and non-specific dipeptidase). Biol. Chem. Hoppe Seyler (1990) 371 433-440.
27. Kunze N., Kleinkauf H., Bauer K. Characterization of two carnosine-degrading enzymes from rat brain. Partial purification and characterization of a carnosinase and a beta-alanyl-arginine hydrolase. Eur. J. Biochem. (1986) 160 605-613.
28. Boldyrev A.A., Dupin A.M., Bunin A.Ya., Babizhayev M.A., Severin S.E. The antioxidative properties of carnosine, a natural histidine containing dipeptide. Biochem. Int. (1987) 15 1105-1113.
29. Aldini G., Facino R.M., Beretta G., Carini M. Carnosine and related dipeptides as quenchers of reactive carbonyl species: from structural studies to therapeutic perspectives. Biofactors (2005) 24 77-87.
30. Aldini G., Orioli M., Carini M., Maffei Facino R. Profiling histidine-containing dipeptides in rat tissues by liquid chromatography/electrospray ionization tandem mass spectrometry. J. Mass Spectrom. (2004) 39 1417-1428.
31. Orioli M., Aldini G., Beretta G., Facino R.M., Carini M. LC-ESI-MS/MS determination of 4-hydroxy-trans-2-nonenal Michael adducts with cysteine and histidine-containing peptides as early markers of oxidative stress in excitable tissues. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2005) 827 109-118.
32. Reddy V.P., Garrett M.R., Perry G., Smith M.A. Carnosine: a versatile antioxidant and antiglycating agent. Sci. Aging Knowledge Environ. (2005) 2005 pe 12.
33. Rashid I., van Reyk D.M., Davies M.J. Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro. FEBS Lett. (2007) 581 1067-1070.
34. Arnould J.M., Frentz R. Presence, isolation and chemical structure of a substance characteristic of cardiac tissue in Carcinus maenas (L.): beta-alanylhistamine. Comp. Biochem. Physiol. C. (1975) 50 59-66.
35. Brotman D.N., Flancbaum L., Fitzpatrick J.C., Fisher H. Presence of carcinine (β-alanylhistamine) in mammalian tissues. FASEB J. (1989) 3 1028.
36. Brotman D.N., Flancbaum L., Kang Y.H., Merrill G.F., Fisher H. Positive inotropic effects of carcinine in the isolated, perfused guinea pig heart. Crit. Care Med. (1990) 18 317-321.
37. Flancbaum L., Brotman D.N., Fitzpatrick J.C., Van Es T., Kasziba E., Fisher H. Existence of carcinine, a histamine-related compound, in mammalian tissues. Life Sci. (1990) 47 1587-1593.
38. Ali S.M., Tedford C.E., Gregory R. et al. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists. J. Med. Chem. (1999) 42 903-909.
39. Tedford C.E., Phillips J.G., Gregory R. et al. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands. J. Pharmacol. Exp. Ther. (1999) 289 1160-1168.
40. Yates S.L., Phillips J.G., Gregory R. et al. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands. J. Pharmacol. Exp. Ther. (1999) 289 1151-1159.
41. Tozer M.J., Kalindjian S.B. Histamine H3 receptor antagonists. Expert Opin. Ther. Patents (2000) 10 1045-1055.
42. Chen Z., Sakurai E., Hu W. et al. Pharmacological effects of carcinine on histaminergic neurons in the brain. Br. J. Pharmacol. (2004) 143 573-580. Epub 2004 Oct 4.
43. Babizhayev M.A. Biological activities of the natural imidazole-containing peptidomimetics n-acetylcarnosine, carcinine and L-carnosine in ophthalmic and skin care products. Life Sci. (2006) 78 2343-2357. Epub 2006 Jan 4.
44. Arnould J.M., Frentz R. Carcinine (β-alanyl-histamine): rapid synthesis and action on vertebrate blood pressure. Arch. Int. Physiol. Biochim. (1977) 85 339-350.
45. Babizhayev M.A., Deyev A.I., Yermakova V.N. et al. Image analysis and glare sensitivity in human age-related cataracts. Clin. Exp. Optom. (2003) 86 157-172.
46. Babizhayev M.A. Glare disability and driving safety. Ophthalmic Res. (2003) 35 19-25.
47. Babizhayev M.A., Seguin M.-C. Process of assessment of ocular dysfunctions and implementation devices of this process. US Patent No. 6, 007, 203. Date of patent: December 28, 1999.
48. Ferris F.L., Kassoff A., Bresnick G.H. et al. New visual acuity charts for clinical research. Am. J. Ophthalmol. (1982) 94 91-96.
49. Ferris F.L., Sperduto R.D. Standardized illumination for visual acuity testing in clinical research. Am. J. Ophthalmol. (1982) 94 97-98.
50. Khoroshilova-Maslova I.P., Babizhayev M.A., Ilatovskaya L.V., Kiseleva O.A., Gankovskaya L.V. Method of prophylaxis of proliferative vitreoretinopathy. Moscow Helmholtz Institute for Eye Diseases. Russian Patent No. 2175223. Patent issued on 27 October 2001. Priority of 29.07.1999.
51. Kanan Y., Wicker L.D., Al-Ubaidi M.R., Mandal N.A., Kasus-Jacobi A. Retinol dehydrogenases RDH11 and RDH12 in the mouse retina: expression levels during development and regulation by oxidative stress. Invest. Ophthalmol. Vis. Sci. (2008) 49 1071-1078.
52. Babizhayev M.A. Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery. Drug Dev. Ind. Pharm. (2008) 34 1071-1089.
53. Rekker R.F. The hydrophobic fragmental constant. Elsevier, Amsterdam, 1977.
54. O'Dowd J.J., Robins D.J., Miller D.J. Detection, characterisation, and quantification of carnosine and other histidyl derivatives in cardiac and skeletal muscle. Biochim. Biophys. Acta (1988) 967 241-249.
55. Babizhayev M.A., Yermakova V.N., Semiletov Y.A., Deyev A.I. The natural histidine-containing dipeptide N-acetylcarnosine as an antioxidant for ophthalmic use. Biochemistry (Mosc) (2000) 65 588-598.
56. Hepsen I.F., Yildirim Z., Yilmaz H., Kotuk M. Preventive effect of lacrimal occlusion on topical timolol-induced bronchoconstriction in asthmatics. Clin. Experiment. Ophthalmol. (2004) 32 597-602.
57. Otani H., Okumura A., Nagai K., Okumura N. Colocalization of a carnosine-splitting enzyme, tissue carnosinase (CN2)/cytosolic non-specific dipeptidase 2 (CNDP2), with histidine decarboxylase in the tuberomammillary nucleus of the hypothalamus. Neurosci. Lett. (2008) 445 166-169. Epub 2008 Sep 7.
58. Uhlrich D.J., Manning K.A., Xue J.-T. Effects of activation of the histaminergic tuberomammillary nucleus on visual responses of neurons in the dorsal lateral geniculate nucleus. J. Neurosci. (2002) 22 1098-1107.
59. Panula P., Pirvola U., Auvinen S., Airaksinen M.S. Histamine-immunoreactive nerve fibers in the rat brain. Neuroscience (1989) 28 585-610.
60. Pegova A., Abe H., Boldyrev A. Hydrolysis of carnosine and related compounds by mammalian carnosinases. Comp. Biochem. Physiol. B Biochem. Mol. Biol. (2000) 127 443-446.
61. Haddad G., Belosevic M. Transferrin-derived synthetic peptide induces highly conserved pro-inflammatory responses of macrophages. Mol. Immunol. (2009) 46 576-586. Epub 2008 Oct 25.
62. Wenzel A., Grimm C., Samardzija M., Remâe C.E. Molecular mechanisms of light-induced photoreceptor apoptosis and neuroprotection for retinal degeneration. Prog. Retin. Eye Res. (2005) 24 275-306.
63. Awasthi Y.C., Sharma R., Cheng J.Z. et al. Role of 4-hydroxynonenal in stress-mediated apoptosis signaling. Mol. Aspects Med. (2003) 24 219-230.
64. Yang Y., Sharma R., Sharma A., Awasthi S., Awasthi Y.C. Lipid peroxidation and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling. Acta Biochim. Pol. (2003) 50 319-336.
65. Tanito M., Elliott M.H., Kotake Y., Anderson R.E. Protein modifications by 4-hydroxynonenal and 4-hydroxyhexenal in light-exposed rat retina. Invest. Ophthalmol. Vis. Sci. (2005) 46 3859-3868.
66. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid Res. (2003) 42 318-343.
67. Uchida K., Stadtman E R. Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc. Natl Acad. Sci. USA (1992) 89 4544-4548.
68. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. (1991) 11 81-128.
69. Esterbauer H. Cytotoxicity and genotoxicity of lipid-oxidation products. Am. J. Clin. Nutr. (1993) 57 779S-785S. discussion 785S-786S.
70. Kasus-Jacobi A., Ou J., Birch D.G. et al. Functional characterization of mouse RDH11 as a retinol dehydrogenase involved in dark adaptation in vivo. J. Biol. Chem. (2005) 280 20413-20420.
71. Owsley C., Stalvey B.T., Wells J., Sloane M.E., McGwin G. Jr. Visual risk factors for crash involvement in older drivers with cataract. Arch. Ophthalmol. (2001) 119 881-887.
72. Eye Research Australia, Access Economics (2004) Clear insight: the economic impact and cost of vision loss in Australia. Access Economics, Melbourne.
73. Taylor H.R., McCarty C.A., Nanjan M.B. Vision impairment predicts five-year mortality. Trans. Am. Ophthalmol. Soc. (2000) 98 91-96.
74. Weih L.M., Hassell J.B., Keeffe J. Assessment of the impact of vision impairment. Invest. Ophthalmol. Vis. Sci. (2002) 43 927-935.
75. Klein B.E., Klein R., Jensen S.C. A short questionnaire on visual function in older adults to supplement ophthalmic examination. Am. J. Ophthalmol. (2000) 130 350-352.
76. Haymes S.A., Johnston A.W., Heyes A.S. The development of the Melbourne Low Vision ADL Index: a measure of vision disability. Invest. Ophthalmol. Vis. Sci. (2001) 42 1215-1225.
77. Friedman S.M., Munoz B., Rubin G.S., West S.K., Bandeen-Roche K., Fried L.P. Characteristics of discrepancies between self-reported visual function and measured reading speed. Invest. Ophthalmol. Vis. Sci. (1999) 40 858-864.
78. McCarty C.A., Fu C.L., Taylor H.R. Predictors of falls in the Melbourne visual impairment project. Aust. N. Z. J. Public Health (2002) 26 11611-11619.
79. Wang J.J., Mitchell P., Simpson J.M., Cumming R.G., Smith W. Visual impairment, age-related cataract, and mortality. Arch. Ophthalmol. (2001) 119 1186-1190.
80. Babizhayev M.A., Deyev A.I. Lens opacity induced by lipid peroxidation products as a model of cataract associated with retinal disease. Biochim. Biophys. Acta (1989) 1004 124-133.
81. Fishman G.A., Baca W., Alexander K.R., Derlacki D.J., Glenn A.M., Viana M. Visual acuity in patients with best vitelliform macular dystrophy. Ophthalmology (1993) 100 1665-1670.
82. Wu D.Z., Wu L., Chang F.X., Jin C., Padula W. Visual rehabilitation in low vision patients with aging macular degeneration. J. Am. Optom. Assoc. (1995) 66 39-41.
83. The Retinal Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology (1983) 90 121-125.
84. Kampik A., Kenyon K.R., Michels R.G., Green W.R., de la Cruz Z.C. Epiretinal and vitreous membranes: comparative study of 56 cases. Arch. Ophthalmol. (1981) 99 1445-1454.
85. Jerdan J.A., Pepose J.S., Michels R.G. et al. Proliferative vitreoretinopathy membranes. An immunohistochemical study. Ophthalmology (1989) 96 801-810.
86. Morino P., Hiscott P., McKechnie N., Grierson I. Variation in epiretinal membrane components with clinical duration of the proliferative tissue. Br. J. Ophthalmol. (1990) 74 393-399.
87. Rachal W.F., Burton T.C. Changing concepts of failures after retinal detachment surgery. Arch. Ophthalmol. (1979) 97 480-483.
88. Peyman G.A., Schulman J. Proliferative vitreoretinopathy and chemotherapeutic agents. Surv. Ophthalmol. (1985) 29 434-442.
89. Babizhayev M.A., Seguin M.-C. Pseudodipeptide product having an imidazole grouping and applications. Patent PCT/FR94/01272. Filed 3 Nov. 1994. WO 95/12581.
90. Babizhayev M.A., Seguin M.-C. Coupling product obtained from histamine and an amino acid. Patent PCT/FR94/00189. Filed 21 February 1994. WO 94/19325.
91. Babizhayev M.A., Courbebaisse Y., Nicolay J.-F., Semiletov Y.A. Design and biological activity of imidazole-containing peptidomimetics with a broad-spectrum antioxidant activity. Lett. Pept. Sci. (1998) 5 163-169.
92. Babizhayev M.A., Lozovskaya E.L., Makareyeva E.N., Lul'kin Y.A., Sapezhinskii I.I. Photoprotector and antioxidant properties of histamine-containing peptidomimetics in the photooxidation of glycyltryptophan. Biochemistry (Mosc) (1998) 63 523-528.
93. Belikova N.A., Tyurina Y.Y., Borisenko G. et al. Heterolytic reduction of fatty acid hydroperoxides by cytochrome c/cardiolipin complexes: antioxidant function in mitochondria. J. Am. Chem. Soc. (2009) 131 11288-11289.
94. Kagan V.E., Bayir H.A., Belikova N.A. et al. Cytochrome c/cardiolipin relations in mitochondria: a kiss of death. Free Radic. Biol. Med. (2009) 46 1439-1453. Epub 2009 Mar 12.
95. Tyurin V.A., Tyurina Y.Y., Jung M.Y. et al. Mass-spectrometric analysis of hydroperoxy- and hydroxy-derivatives of cardiolipin and phosphatidylserine in cells and tissues induced by pro-apoptotic and pro-inflammatory stimuli. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2009) 877 2863-2872. Epub 2009 Mar 13.
96. Kagan V.E., Bayir A., Bayir H. et al. Mitochondria-targeted disruptors and inhibitors of cytochrome c/cardiolipin peroxidase complexes: a new strategy in anti-apoptotic drug discovery. Mol. Nutr. Food Res. (2009) 53 104-114.
97. McKechnie N.M., Fould W.S. Qualitative observations on the variations of light induced damage to the rabbit retina. Graefes. Arch. Clin. Exp. Ophthalmol. (1981) 215 305-325.
98. Duncan T.E., O'Steen W.K. The diurnal susceptibility of rat retinal photoreceptors to light induced damage. Exp. Eye Res. (1985) 41 497-507.
99. Kremers J.J.M., Norren D.V. Retinal damage in macaque after white light exposures lasting ten minutes to twelve hours. Invest. Ophthalmol. Vis. Sci. (1989) 30 1032-1040.
100. Lee F.L., Yu D.Y., Tso M.O.M. Effect of continuous versus multiple intermittent light exposures on rat retina. Curr. Eye Res. (1990) 9 11-21.
101. Rapp L.M., Tolman B.L., Dhindsa H.S. Separate mechanisms for retinal damage by ultraviolet-A and mid-visible light. Invest. Ophthalmol. Vis. Sci. (1990) 31 1186-1190.
102. Penn J.S., Howard A.G., Williams T.P. Light damage as a function of "light history" in albino rat, in: La Vail M.M., Hollyfield J.G., Anderson R.G. (Eds). Retinal degeneration: experimental and clinical studies. Alan R. Liss, New York, 1985, pp. 439-447.
103. White M.P., Fisher L.J. Degree of light damage to the retina varies with time of day of bright light exposure. Physiol. Behav. (1987) 39 607-613.
104. Noell W.K. Retinal damage by light in rats. Invest. Ophthalmol. Vis. Sci. (1966) 5 450-473.
105. Wiegand R.D., Guisto N.M., Rapp L.M., Anderson R.E. Evidence for rod outer segment lipid peroxidation following constant illumination of the rat retina. Invest. Ophthalmol. Vis. Sci. (1983) 24 l433-l435.
106. Organisciak D.T., Wang H.M., Li Z.Y., Tso M.O.M. The protective effect of ascorbate in retinal light damage of rats. Invest. Ophthalmol. Vis. Sci. (1985) 26 1580-1588.
107. Feeney L., Berman E.R. Oxygen toxicity: membrane damage by free radicals. Invest. Ophthalmol. Vis. Sci. (1976) 15 789-792.
108. Li Z.Y., Tso M.O.M., Wang H.M., Organisciak D.T. Amelioration of photic injury in rat retina by ascorbic acid. Invest. Ophthalmol. Vis. Sci. (1985) 26 1589-1598.
109. Organisciak D.T., Bicknell I.R., Darrow R.M. The effect of L and D ascorbic acid administration on retinal tissue levels and light damage in rats. Curr. Eye Res. (1992) 11 231-241.
110. Ham W.T., Muller H.A., Ruffolo J.J. et al. Basic mechanisms underlying the production of photochemical lesions in the mammalian retina. Curr. Eye Res. (1984) 3 165-174.
111. Aust S.D., Morehouse L.A., Thomas C.E. Role of metals in oxygen radical reactions. Free Radic. Biol. Med. (1985) 1 3-25.
112. Fliesler S.J., Anderson R.E. Chemistry and metabolism of lipids in the vertebrate retina. Prog. Lipid Res. (1983) 22 79-131.
113. Rodieck R.W. The vertebrate retina: principles of structure and function. WH Freeman, San Francisco, 1973.
114. Girotti A. Photodynamic lipid peroxidation in biological systems. Photochem. Photobiol. (1990) 51 497-509.
115. Babizhayev M.A., Meguro K. (2004) Combined use of carnosinase inhibitor with l-carnosines and composition. WO 2004/064866 PCT/JP2004/000351. Filed 20 January 2003 (20.01.2003).
116. Babizhayev M.A. Method for topical treatment of eye disease and composition and device for said treatment. United States Patent No. US 7, 795, 203 B2, Date of Patent Sep. 14, 2010, PCT filed: Sep. 29, 2003 PCT No. PCT/IB03/04259.
117. Babizhayev M.A., Yegorov Y.E. Advanced drug delivery of N-acetylcarnosine (N-acetyl-beta-alanyl-L-histidine), carcinine (beta-alanylhistamine) and L-carnosine (beta-alanyl-L-histidine) in targeting peptide compounds as pharmacological chaperones for use in tissue engineering, human disease management and therapy: from in vitro to the clinic. Recent Pat. Drug Deliv. Formul. (2010) 4 198-230.
118. Babizhayev M.A., Yegorov Y.E. Therapeutic uses of drug-carrier systems for imidazole-containing dipeptide compounds that act as pharmacological chaperones and have significant impact on the treatment of chronic diseases associated with increased oxidative stress and the formation of advanced glycation end products. Crit. Rev. Ther. Drug Carrier Syst. (2010) 27 85-154.
119. Babizhayev M.A. Designation of imidazole-containing dipeptides as pharmacological chaperones. Hum. Exp. Toxicol. (2010) [Epub ahead of print].